Carboplatin and bevacizumab for recurrent malignant glioma

Oncology Letters

Volumn 4, Issue 5, 2012, Pages 1082-1086

  Mrugala, Maciej M ^a   Crew, Laurie K ^a   Fink, James R ^a   Spence, Alexander M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Anti VEGF therapy; Carboplatin; Malignant glioma

Indexed keywords

BEVACIZUMAB; CARBOPLATIN;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; HERPES ZOSTER ENCEPHALITIS; HUMAN; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; RECURRENT CANCER; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

EID: 84866100889     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.839     Document Type: Article

References (22)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, etal: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
2. Fulton D, Urtasun R and Forsyth P: Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 27: 149-155, 1996.
3. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, KerbyT, Lawyer J, Parry M, et al: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17: 1516-1525, 1999.
4. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, PradosMD, Brada M, et al: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000.
5. Warnick RE, Prados MD, Mack EE, Chandler KL, Doz F, RabbittJE and Malec MK: A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 19: 69-74, 1994.
6. Wang Y, Fei D, Vanderlaan M and Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7: 335-345, 2004.
7. Stark-Vance V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Abstracts from the World Federation of Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-Oncology. Neuro-Oncol 7: abstract 342, 2005.
8. Vredenburgh JJ, Desjardins A, Herndon JE II, MarcelloJ, ReardonDA, Quinn JA, Rich JN, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729, 2007.
9. Vredenburgh JJ, Desjardins A, Herndon JE II, DowellJM, Reardon DA, Quinn JA, Rich JN, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259, 2007.
10. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, etal: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740, 2009.
11. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, GarrenN, et al: PhaseII trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27: 740-745, 2009.
12. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, et al: Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101: 1986-1994, 2009.
13. Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendonRE, Marcello J, Herndon JE, Mathe A, et al: Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 12: 1300-1310, 2010.
14. Desjardins A, Reardon DA, Coan A, Marcello J, HerndonJEII, Bailey L, Peters KB, et al: Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118: 1302-1312, 2012.
15. Reardon DA, Desjardins A, Peters KB, Gururangan S, SampsonJH, McLendon RE, Herndon JE II, et al: Phase II study of carboplatin, irinotecan and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol 107: 155-164, 2012.
16. Francesconi AB, Dupre S, Matos M, Martin D, Hughes BG, Wyld DK and Lickliter JD: Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci 17: 970-974, 2010.
17. Thompson EM, Dosa E, Kraemer DF and Neuwelt EA: Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery 67: 87-93, 2010.
18. Yung WK, Mechtler L and Gleason MJ: Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9: 860-864, 1991.
19. Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, MilojevicL, Djuric L and Mijatovic L: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phaseII study. J Clin Oncol 10: 1074-1077, 1992.
20. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
21. Jain RK: Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19: 7-16, 2005.
22. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, et al: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787, 2008.